Skip to content

Advertisement

  • Research
  • Open Access

Protein disulfide isomerase as a prosurvival factor in cell therapy for muscular and vascular diseases

Contributed equally
Stem Cell Research & Therapy20189:250

https://doi.org/10.1186/s13287-018-0986-y

  • Received: 4 June 2018
  • Accepted: 17 August 2018
  • Published:

Abstract

Background

Cell therapy for degenerative diseases aims at rescuing tissue damage by delivery of precursor cells. Thus far, this strategy has been mostly unsuccessful due to massive loss of donor cells shortly after transplantation. Several strategies have been applied to increase transplanted cell survival but only with limited success. The endoplasmic reticulum (ER) is an organelle involved in protein folding, calcium homeostasis, and lipid biosynthesis. Protein disulfide isomerase (PDI) is a molecular chaperone induced and activated by ER stress. PDI is induced by hypoxia in neuronal, cardiac, and endothelial cells, supporting increased cell survival to hypoxic stress and protection from apoptosis in response to ischemia.

Methods

We achieved ex vivo PDI gene transfer into luciferase-expressing myoblasts and endothelial cells. We assessed cell engraftment upon intramuscular transplantation into a mouse model of Duchenne muscular dystrophy (mdx mouse) and into a mouse model of ischemic disease.

Results

We observed that loss of full-length dystrophin expression in mdx mice muscle leads to an increase of PDI expression, possibly in response to augmented ER protein folding load. Moreover, we determined that overexpression of PDI confers a survival advantage for muscle cells in vitro and in vivo to human myoblasts injected into murine dystrophic muscle and to endothelial cells administered upon hindlimb ischemia damage, improving the therapeutic outcome of the cell therapy treatment.

Conclusions

Collectively, these results suggest that overexpression of PDI may protect transplanted cells from hypoxia and other possibly occurring ER stresses, and consequently enhance their regenerative properties.

Keywords

  • Cell and tissue-based therapy
  • Cell survival
  • Duchenne muscular dystrophy
  • Endoplasmic reticulum stress
  • Endothelial cells
  • Ischemia
  • Molecular chaperones
  • Myoblasts
  • Protein disulfide isomerase
  • Regenerative medicine

Background

Maintenance and regeneration of skeletal muscles mainly depend on resident stem cells known as satellite cells. The satellite cell pool that takes part in myofiber repair is progressively exhausted with age [1] and in muscle degenerative disorders characterized by repetitive cycles of muscle degeneration and regeneration, such as Duchenne muscular dystrophy (DMD) [2]. Cell therapy approaches for degenerative muscle diseases aim at rescuing muscle damage by delivery of cells able to differentiate into skeletal muscle [3, 4]. Satellite cells represent the primary choice for cell-based therapy due to their commitment to the myogenic lineage [5, 6]. However, satellite cells from muscle biopsies are recovered in low numbers, grow poorly in vitro, and rapidly undergo senescence [7] as a consequence of replicative aging associated with telomere shortening [8]. The reduced capacity to proliferate during the step of in vitro amplification hampers the clinical translation of possible satellite cell-based therapies for DMD [3, 9]. In addition, cellular polarity is lost in dystrophin-deficient satellite cells, leading to asymmetric cell division, improper differentiation, and consequently to an overall reduction in the number of myogenic progenitor cells [6]. To date, myoblast transplantation treatment has been generally ineffective given that the functional support of engrafted cells is limited due to massive donor cell death shortly after transplantation [1012]. Several studies have shown that freshly isolated, uncultured satellite cells, as well as satellite cells still enclosed in their myofiber niche, regenerate muscle much more efficiently than cells exposed to culture conditions, so that very low numbers of such cell are necessary for regenerative purposes compared to cultured cells [13, 14]. However, genetic correction of mutated cells, as would be required in the case of a homologous transplant, requires ex vivo culture and expansion. Therefore, further studies aimed at defining more valid strategies to prevent myoblast death in the early stage after transplantation are required [15]. Direct muscle injection exposes transplanted cells to prolonged periods of hypoxia, particularly exacerbated in dystrophic muscles which are characterized by high levels of reactive oxygen species (ROS) [16].

Loss of function mutations in the gene encoding for the 427-kDa cytoskeletal protein dystrophin cause DMD. Dystrophin has a structural role in muscle, connecting the cytoskeleton to the basal lamina. When functional dystrophin is absent, skeletal muscle signaling is disrupted, leading to progressive damage and membrane leakage, to fiber degeneration and necrosis [17]. The mdx mouse harbors a point mutation in the dystrophin gene and is considered a surrogate model for DMD [18]. Interestingly, the full-length and shorter isoforms of dystrophin are highly transcribed in the satellite cells from wild-type and mdx mice, respectively [19]. Unfolded fragments of dystrophin produced from the mdx premature termination codon accumulate in the endoplasmic reticulum (ER)/Golgi compartments triggering ER stress, resulting in activation of the unfolded protein response (UPR) [20]. To counteract the accumulation of unfolded proteins, UPR activation leads to upregulation of ER resident chaperones, reduction of protein translation, and increase in the degradation of unfolded proteins [21]. However, if the stress is severe and/or prolonged, the ER also initiates apoptotic signaling and promotes production of ROS [22]. Thus, ER stress response has relevant implications in deciding cell survival or death [23]. Remarkably, the rate of accumulation of unfolded proteins is likely to be much higher in satellite cells than in cells with a higher turnover rate, making satellite cells more exposed to proteotoxicity linked to altered protein homeostasis [24].

Protein disulfide isomerase (PDI) and its related family members are among the ER chaperones upregulated upon UPR activation [25]. PDI has two enzymatic activities: as an oxidoreductase, it can catalyze the formation, reduction, and isomerization of disulfide bonds; and as a polypeptide binding protein, it works as a molecular chaperone supporting the folding of nascent polypeptides, consequently increasing the yield of correctly folded protein molecules [26, 27]. Disulfide bond formation and proper protein folding occur in the ER. In addition, PDI has a copper binding activity which plays a key role in regulating intracellular disposition of this redox-active metal; PDI may also control the function of certain extracellular matrix proteins by regulating their redox state [28]. PDI prevents neurotoxicity associated with ER stress and protein misfolding in neurodegenerative disorders such as Parkinson’s or Alzheimer’s disease [29]. Upregulation of PDI in response to hypoxia has been demonstrated in neuronal, cardiac, and endothelial cells. Overexpression of PDI in these cells results in an increase of cell viability in response to hypoxia and protection from apoptosis in response to ischemia [30]. However, the possible involvement of ER stress-associated proteins, and in particular of molecular chaperones such as PDI, in the skeletal muscle system and in its degenerative pathologies has been only partially investigated [31].

In this report we evaluated PDI expression in skeletal muscle of mdx mice in comparison with their wild-type counterpart. Moreover, we tested the hypothesis that viral-mediated overexpression of PDI might be instrumental in promoting survival and engraftment of primary myoblasts transplanted into mdx mice, possibly increasing the therapeutic efficacy of the procedure. Furthermore, we evaluated a similar strategy to promote a cell therapy intervention aimed at promoting angiogenesis in a mouse model of hindlimb ischemia.

Methods

Experimental animal procedures

Procedures involving living animals were approved by local ethics committees and were performed according to the Guidelines of the Italian National Institutes of Health (Art. 31 D.lgs 26/2014, 4 March 2014). Animals used in the study were 3-month-old dystrophic C57BL/ 10ScSn Dmdmdx and age-matched wild-type control mice provided by Charles River (Calco, Lecco, Italy). Postoperatively, animals were administered by intraperitoneal injection of the clinically approved immunosuppressive drug tacrolimus (FK-506; Sigma-Aldrich St. Louis, MO, USA) 2 mg/kg per day [32]. Acute hindlimb ischemia was induced by removal of the femoral artery, as described previously [33]. Measure of the blood flow in the ischemic hindlimb compared to the contralateral control was performed by laser Doppler perfusion imaging (Lisca Inc., North Brunswick, NJ, USA).

Cell culture

Human primary myoblasts were obtained from ThermoFisher Scientific (Waltham, MA, USA) and cultured according to the manufacturer’s instructions. Human endothelial cells were isolated from adipose tissue collected during cosmetic surgery procedures, as described previously [34]. Each subject gave her/his written informed consent to use harvested adipose tissue samples for research purposes. The study protocol was approved by the Institutional Review Board (n° 1794/15, 13/02/2015) and was performed in accordance with the principles of Good Clinical Practice expressed in the Declaration of Helsinki. The C2C12 immortalized muscle cell line derived from CH3 wild-type mice were cultured in accordance with the American Type Culture Collection specifications in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Grand Island, NY, USA) supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin–streptomycin solution (50 U/ml penicillin and 50 μg/ml streptomycin), at 37 °C in a humidified atmosphere of 95% air and 5% CO2. Before administration cells were counted, resuspended in 25 μl of phosphate-buffered saline (PBS), and delivered into the tibialis anterior muscle of the experimental animals.

Endoplasmic reticulum stress induction and cell proliferation analysis

Tunicamycin, a mixture of antiviral nucleoside antibiotics; thapsigargin, an inhibitor of the ubiquitous sarcoplasmic reticulum/endoplasmic reticulum Ca++ ATPase; and MG132, a specific proteasome inhibitor that blocks ER-associated protein degradation, are commonly used as pharmaceutical ER stress inducers [35]. C2C12 cells (2 × 105 cells) were plated on 60-mm dishes and cultured in medium supplemented with either 5.0 μg/μl tunicamycin, 0.5 μM thapsigargin, or 10.0 μM MG132 (all from Sigma-Aldrich) for 6 h at 37 °C. Cell proliferation after treatment was measured using the WST-1 cell proliferation assay kit (Takara, Clontech, Mountain View, CA, USA), according to the manufacturer’s instructions. The optical density at 450 nm was assessed using a microplate reader (BioRad Laboratories Inc., Hercules, CA, USA). All experiments were performed at least twice in duplicate, and the relative cell viability (%) was expressed as a percentage relative to the untreated control cells.

The plant flavonoid quercetin has protective effects on ER stress in intestinal epithelial cells [36]. On this basis, C2C12 cells were treated with quercetin (75 μM) (Sigma-Aldrich) for 24 h and then challenged either with tunicamycin (0.3 μM) or thapsigargin (1.5 μg/ml) for an additional 16 h before collection for western blot analysis and cell proliferation assay.

Viral vector production and viral-mediated gene transfer

Recombinant E1–E3-deleted adenoviral vectors expressing GFP used as control or PDI and GFP (PDI-GFP) were produced as described previously [30]. Third-generation, self-inactivating, recombinant vesicular stomatitis virus-pseudotyped lentiviral vectors (LV) expressing firefly luciferase were obtained as reported previously [37]. Viral-mediated gene transfer in human primary myoblasts and endothelial cells was performed as described previously [32, 37]. Transduction of C2C12 cells was achieved with transfection with Lipofectamine LTX (ThermoFisher Scientific).

Immunoblotting analysis

For western blot analysis, cells (1.5 × 105 cells/60-mm dish) were collected and protein lysates were loaded on polyacrylamide gel. Following SDS-PAGE, immunoblot analysis was performed according to established protocols using the following primary antibodies: anti-poly(ADP-ribose) polymerase (PARP), anti-binding immunoglobulin protein (GRP78/BiP), endoplasmic reticulum oxidoreductin-1α (ERO1α), anti-PDI (Cell Signaling Technology, Danvers, MA, USA), and anti-p21 (Santa Cruz Biotechnology, Dallas, TX, USA). Glyceraldehyde phosphate dehydrogenase (GAPDH) has been used as the protein loading normalization. Densitometry analysis was performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Optical bioluminescent imaging

For in vivo bioluminescent imaging (BLI) analysis, mice were anesthetized and d-luciferin dissolved in PBS (150 mg/kg body weight) was administered by intraperitoneal injection. Analysis was performed using the IVIS Lumina II instrument equipped with Living Image software for data quantification (PerkinElmer, Waltham, MA, USA), according to an established procedure [38].

Immunohistochemistry

At necropsy, hindlimb muscles were dissected, fixed in formalin for 48 h, and embedded in paraffin, as described previously [39]. Immunohistochemistry on deparaffinized sections was performed using the following antibodies: rabbit polyclonal antibody anti-GFP (Ab290, 10 μg/ml; Abcam, Cambridge, UK), rabbit polyclonal anti-carboxy-terminal portion of dystrophin (Ab15277, 2 μg/ml; Abcam), rabbit polyclonal antibody anti-PDI H-160 (1:200 dilution; Santa Cruz Biotechnology), and rabbit polyclonal antibody against firefly luciferase (1:500 dilution; Sigma Aldrich). For immunofluorescence studies, sections were processed with fluorochrome-conjugated anti-rabbit antibody (1:40 dilution; Dako/Agilent Technologies, Santa Clara, CA, USA), stained with Hoechst to identify nuclei, and mounted in Vectashield (Vector Laboratories, Burlingame, CA, USA). Images were acquired with a fluorescence microscope equipped with image analyzer KS300 software (Carl Zeiss, Oberkochen, Germany).

Statistical analysis

Results are expressed as mean ± standard error of the mean. Data analysis and comparisons between groups were done with INSTAT software (GraphPad, San Diego, CA, USA). The significance of differences was assessed with a two-tailed Student t test for unpaired data; statistical significance was set at p < 0.05.

Results

Protein disulfide isomerase levels are increased in mdx versus wild-type skeletal muscle

The mdx mouse is the most common animal model used in DMD research. In the mdx mouse, the dystrophin gene contains a premature stop codon in exon 23; the lack of full-length dystrophin protein is linked with higher protein turnover [40], with a compensatory higher expression of utrophin [41], filamin 2, cytoplasmic γ-actin [42], and α7β1 integrin [43]. Accumulation of truncated, misfolded dystrophin in the ER and enhanced expression of several other proteins, some of which, such as the β1 integrin subunit, are naturally rich in disulfide bonds, may result in upregulation of ER chaperones like PDI. In skeletal muscle, resident ER chaperones, in addition to occupying ER perinuclear regions, are distributed within all of the sarcoplasmic reticulum [44]. To assess the level of expression and the localization of PDI in muscle sections of wild-type and mdx mice, we performed immunohistochemistry using a specific anti-PDI antibody. We revealed that PDI expression is stronger in mdx regenerating muscle (Fig. 1), suggesting a possible induction of ER stress caused by accumulation of the misfolded truncated form of dystrophin [20]. This result is consistent with previous reports indicating increased levels of some ER stress markers, including GRP78, PERK, eIF2a, IRE1, sXBP1 [45], and CHOP [46] in skeletal muscle from dystrophic versus wild-type mice. Therefore, upregulation of PDI expression in mdx muscle may represent a cellular response to the pathological condition aiming at preserving protein homeostasis [45].
Fig. 1
Fig. 1

PDI expression in tibialis anterior muscle in wild-type and mdx mice. Immunohistochemical staining using anti-PDI specific antibodies on representative sections of tibialis anterior muscles isolated from wild-type (a) and mdx (b) mice. Scale bar 50 μm

Endoplasmic reticulum stress induction in vitro reduces muscular cell viability

We investigated the effects of ER stress exposure into the murine mouse myoblast C2C12 cell line, a widely used model to investigate in vitro myoblast proliferation and differentiation. We performed a cell proliferation assay on C2C12 cells upon ER stress induced by tunicamycin, thapsigargin, and MG132. We observed that the treatments affected short-term proliferation and survival of C2C12 cells (Fig. 2a), thus indicating that ER stress determined a reduction of muscular cell proliferation and viability. In addition, in response to ER stress induced by tunicamycin treatment we observed by immunoblot analysis a marked activation of the binding immunoglobulin protein (GRP78/BiP), a marker of ER stress, and the cleavage of poly(ADP-ribose) polymerase (PARP), a hallmark of apoptosis (Fig. 2b). Thus, under ER stress conditions, muscular cells activate GRP78/BiP overexpression aiming at rescuing cells from the effects of accumulation of misfolded proteins. Acute and unresolved ER stress may lead to apoptotic cell death. Alleviation of ER stress by may therefore help in reestablishing ER homoeostasis, reducing apoptosis.
Fig. 2
Fig. 2

ER stress induction affects C2C12 cell proliferation and survival. C2C12 immortalized mouse myoblast cell line (1.5 × 103 cells/60-mm dish) treated with either tunicamycin (Tuni) (5 μg/ml), thapsigargin (Thap) (0.3 μM), MG132 (10 μM), or vehicle solution only (DMSO) as control for 6 h. a Cell proliferation measured using WST-1 cell proliferation assay kit. Results reported as mean ± standard deviation of three independent experiments performed in duplicate. *p < 0.005. b C2C12 cells treated with tunicamycin for 16 h and immunoblot analysis performed using specific antibodies against GRP78/BiP and PARP (full-length and cleaved form) to assess ER stress and apoptotic cell death induction, respectively. GAPDH used as protein loading normalization. DMSO dimethylsulfoxide, ER endoplasmic reticulum, GAPDH glyceraldehyde phosphate dehydrogenase, GRP78/BiP anti-binding immunoglobulin protein, PARP anti-poly(ADP-ribose) polymerase

Protein disulfide isomerase overexpression has prosurvival effects upon endoplasmic reticulum stress induction in vitro

To analyze the potential protective role of PDI in cells under ER stress, we evaluated the effect of PDI overexpression in C2C12 cells. To this aim, cells were transfected with a PDI-GFP-expressing vector and transduction was confirmed using anti-turboGFP specific antibody immunoblot (Fig. 3a). As previously determined (Fig. 2b), ER stress induction in C2C12 muscle cells caused a marked activation of the markers of ER stress GRP78/BiP and endoplasmic reticulum oxidoreductin-1α (ERO1α) and increased levels of the apoptotic marker PARP. Consistently, PDI-overexpressing cells were significantly more resistant to ER stress and apoptosis, clearly showing a reduction in the activation of GRP78/BiP, ERO1α, and cleaved PARP with respect to untreated and mock transduced cells (Fig. 3a). Endoplasmic reticulum stress and UPR induction may also participate in the progress of cellular senescence [47]. Thus, we evaluated the senescence marker p21 [48] in response to ER stress induction (Fig. 3a). Expression of p21 was under the detection limit both in control and PDI-overexpressing cells, regardless of ER stress induction by tunicamycin treatment. Conversely, inhibition of the proteasome by MG132 treatment induced p21 expression, in accordance with the induction of a senescence-like phenotype observed in primary human fibroblasts [49]. Interestingly, MG132-induced upregulation of p21 in PDI-overexpressing cells was reduced compared to untransduced cells, suggesting a possible beneficial effect of PDI expression in reducing the induction of senescence.
Fig. 3
Fig. 3

Protective effect of PDI overexpression and quercetin treatment on ER stress activation, apoptotic cell death, and cell survival. a C2C12 cells (1 × 103 cells/96-well plates) underwent PDI gene transfer 24 h before treatment either with tunicamycin (5 μg/ml) or MG132 (10 μM) for 6 h. Protein lysates (30 μg/lane) analyzed by immunoblot analysis using specific antibodies against PARP (full-length and cleaved form) to assess apoptotic cell death induction. GRP78/BiP and ERO1α assessed as ER stress markers and p21 as cellular senescence marker; antibodies against Turbo GFP used to verify GFP/PDI overexpression. GAPDH used as protein loading normalization. Densitometry performed using ImageJ software and relative band intensities of tunicamycin, and MG132-treated cells normalized to GAPDH and finally quantified with respect to untreated control, arbitrarily set to 1.0. b Mock transfected and PDI-overexpressing C2C12 cells preconditioned with quercetin (75 μM) for 24 h and then challenged with ER stress-inducer tunicamycin (Tuni). Immunoblot and densitometric analysis performed as already described, while (c) cell viability evaluated using WST-1 cell proliferation assay kit. Results reported as mean ± standard deviation of three independent experiments performed in duplicate. *p < 0.005. DMSO dimethylsulfoxide, ERO1α endoplasmic reticulum oxidoreductin-1α, GAPDH glyceraldehyde phosphate dehydrogenase, GFP green fluorescent protein, GRP78/BiP anti-binding immunoglobulin protein, PARP anti-poly(ADP-ribose) polymerase, PDI protein disulfide isomerase

Pharmacological preconditioning might represent an additional strategy to confer ER stress resistance to muscle cells. We therefore also analyzed the effect of preconditioning C2C12 cells with quercetin, which has been characterized as an inhibitor of ER stress [36]. We observed by immunoblot analysis that quercetin pretreatment induced a reduction in both GRP78/BiP and cleaved PARP in tunicamycin-treated C2C12 cells, thus reestablishing ER homoeostasis (Fig. 3b). Further supporting our previously reported data, we could observe, in PDI-overexpressing cells, a reduced induction of both GRP78/BiP and cleaved PARP upon ER stress induction, with respect to untransduced cells (Fig. 3b).

Moreover, by cell proliferation assay we confirmed that PDI-overexpressing cells were significantly more resistant to ER-induced cell death with respect to untransduced controls (Fig. 3c). In addition, we determined that quercetin pretreatment partially protected C2C12 cells from tunicamycin-induced cell death, thus confirming that activation of apoptotic cell death can be mitigated by pharmacological modulation of ER stress. Interestingly, PDI overexpression conferred improved cell survival against ER stress also in combination with quercetin treatment (Fig. 3c). Taken together, these data indicate that the modulation of PDI has an antiapoptotic role in muscular cells promoting ER stress resistance.

Protein disulfide isomerase overexpression promotes engraftment of human myoblasts in mdx mice

PDI is expressed at low basal levels in skeletal, cardiac, and smooth muscle cells [50]. To achieve a more robust PDI expression, we transduced human primary myoblasts with adenoviral constructs encoding both GFP and PDI or GFP only, as described previously [30]. At the same time, cells were also transduced with a lentiviral vector expressing the firefly luciferase gene under the control of a constitutive promoter (Lenti-Luc) [37]. When culture medium was switched from maintenance to differentiation medium the transduced cells promptly differentiated into contractile multinucleated skeletal myotubes, indicating that viral-mediated gene transfer of GFP or PDI-GFP and luciferase does not alter the differentiative ability of human primary myoblasts.

Human myoblasts (1.0 × 105 cells) were directly injected into the tibialis anterior muscle of 2-month-old mdx mice, treated with a daily injection of the immunosuppressant FK-506, beginning on the day of transplant. Engraftment of luciferase-expressing cells was monitored from day 1 to day 7 by in vivo bioluminescent imaging. After 1 week, the persistence of living cells, as measured by bioluminescence, was approximately four times higher (p < 0.05) in animals receiving PDI-GFP-expressing cells versus mice receiving control cells expressing GFP only (Fig. 4). At necropsy, tibialis muscles including regions emitting bioluminescence as assessed by ex vivo BLI imaging (Fig. 4) were collected and processed for further analysis. The presence of luciferase-expressing cells in muscle sections from animals administered PDI-expressing, luciferase-positive myoblasts was confirmed by immunohistochemistry analysis using anti-firefly luciferase antibodies (Fig. 5a). Moreover, immunofluorescence detection of dystrophin protein in muscle sections of transplanted animals indicated that PDI-expressing human cells efficiently engrafted into the muscle, generating dystrophin-expressing fibers (Fig. 5b). Thus, overexpression of PDI seems to confer a survival advantage on transplanted primary myoblasts administered into mdx mice.
Fig. 4
Fig. 4

Monitoring of luciferase-positive human primary myoblasts overexpressing PDI transplanted in mdx mice. Luciferase-positive human myoblasts (1.0 × 105 cells) transduced either with GFP (CTRL) or PDI-GFP (PDI) were injected into tibialis anterior muscle of 2-month-old, immunosuppressed, mdx mice. Engraftment of luciferase-expressing cells monitored from day 1 to day 7 by in vivo bioluminescent imaging and signals in selected area of interest quantified using Living Image software (top panels). At sacrifice, hindlimbs were excised and imaging performed ex vivo (bottom panels). Color bars indicate relative bioluminescent signal intensities from lowest (blue) to highest (red). Values expressed in photons per second per square centimeter per steradian (photons/s/cm2/sr). We determined no difference at earliest time point, while signals detected both by in vivo and ex vivo imaging 1 week after implantation were significantly higher in animals receiving PDI-GFP-expressing cells versus mice receiving control cells. Figure shows a representative animal per group (n = 5). CTRL control, PDI protein disulfide isomerase

Fig. 5
Fig. 5

Engraftment of luciferase-positive, PDI-expressing human cells into mdx muscle generating dystrophin-expressing fibers. Immunohistochemistry analysis of (a) firefly luciferase (green) and (b) human dystrophin (red) expression in representative serial sections of tibialis anterior muscle obtained from mdx mouse after intramuscular administration of human myoblasts expressing luciferase and PDI. Nuclei visualized by Hoechst staining (blue). Scale bar 50 μm

Transplantation of protein disulfide isomerase-overexpressing cells alleviates hindlimb ischemic damage

ER stress has been linked to angiogenesis impairment [51] and to endothelial cell dysfunction [52, 53]. Interestingly, PDI is specifically upregulated in endothelial cells to contribute to their ability to tolerate hypoxic stress [54]. On these bases, we assessed whether PDI overexpression can promote therapeutic angiogenesis supporting the survival of transplanted endothelial cells in a mouse model of hindlimb ischemia [55]. Human dermal white adipose tissue represents a convenient source of cells expressing the endothelial-specific marker platelet endothelial cell adhesion molecule (PECAM-1), also known as cluster of differentiation 31 (CD31), able to form tubular-like structures on a Matrigel assay in vitro and to promote angiogenesis in vivo [34, 56]. We engineered primary human adipose tissue-derived CD31+ endothelial cells to express firefly luciferase in order to perform cell tracking studies by noninvasive BLI. In addition, cells underwent adenoviral viral-mediated gene transfer of either GFP or PDI-GFP. Hindlimb ischemia was induced by removal of the femoral artery [33], and then 2.5 × 105 cells expressing luciferase and GFP or PDI-GFP were delivered into the tibialis anterior muscle of the experimental animals. Bioluminescent imaging performed 1 week after the transplant showed increased emission in animals receiving PDI-expressing cells. The cell transplantation procedure improved whole limb perfusion measured by laser color Doppler analysis performed 1 week after transplant in comparison with mice not receiving the treatment (Fig. 6b), in accordance with a previously described proangiogenic ability of adipose tissue-derived cells in a hindlimb ischemia model [57]. Remarkably, cell transplantation of cells overexpressing PDI displayed further enhanced vascular regenerative ability, compared to animals receiving control cells (Fig. 6b). Moreover, immunohistochemical analysis performed on tissue samples collected at necropsy confirmed the presence of PDI-GFP-positive cells in the vascular endothelial layer at the site of transplant, identified by specific CD31 expression (Fig. 7). Collectively, these data support the hypothesis that preconditioning vascular cells by PDI gene transfer might support survival of cells administered in ischemic tissue promoting therapeutic angiogenesis.
Fig. 6
Fig. 6

Transplantation of human endothelial cells overexpressing PDI into mouse model of hindlimb ischemia. a In vivo bioluminescence analysis of representative mice undergoing experimental ischemia that received transplants of luciferase-expressing human endothelial cells expressing either GFP (CTRL) or PDI and GFP (PDI). Color bar indicates relative bioluminescent signal intensities from lowest (blue) to highest (red). b Laser Doppler scanning of blood flow over hindlimbs 1 week after critical limb ischemia. Quantification of measurements expressed as ischemic vs contralateral nonischemic whole limb perfusion ratios in untreated (Isc) and experimental groups administered with GFP (CTRL) and PDI-GFP (PDI)-expressing cells (n = 5). Perfusion ratio before ischemia (Norm) shown as reference. *p < 0.05. GFP green fluorescent protein, PDI protein disulfide isomerase

Fig. 7
Fig. 7

Engraftment of luciferase-positive PDI-expressing human cells into vascular endothelial layer after hindlimb ischemia. Representative fluorescence images obtained with antibodies against (a) CD31 (red) and (b) PDI (red) in representative sections obtained from mouse receiving human endothelial cells expressing luciferase and PDI-GFP, 1 week after induction of ischemia. Nuclei visualized by Hoechst staining (blue). Scale bar 50 μm

Discussion

Cell therapy represents an emerging approach for the treatment of different pathologies including muscular degenerative diseases and cardiovascular pathologies [58]. Cell therapy positive effects are attributable to both cell restoration eliciting functional tissue repair and paracrine action associated with production of growth factors, cytokines, and extracellular vesicles that promote the endogenous mechanisms of tissue regeneration. So far, several cell therapy clinical trials have suffered from limited or transient efficacy, mainly due to poor survival of transplanted cells soon after in vivo delivery [58]. Transplanted cell loss may be initiated by different events including: anoikis, due to the need to detach anchorage-dependent cells from their substrate for injection; inflammation-related factors, such as exposure to cytokines, natural killer cells, and free radicals at the site of transplant; and oxygen and nutrient shortage, due to the absence of a vasculature network within the injected cell clumps [59]. Perturbations of cellular redox regulation and nutrient deprivation can cause accumulation of unfolded proteins generating ER stress [60].

Skeletal and cardiac muscle fibers are characterized by the presence of the sarcoplasmic reticulum, a specialized network of ER that regulates protein homeostasis and calcium concentration [61]. In response to environmental and genetic factors causing ER stress, muscle cells activate the UPR pathways that play pivotal roles in muscle stem cell homeostasis and in muscle regeneration [62]. Low ER stress, eliciting an adaptive UPR response, promotes resistance to a subsequent pathological insult: a process named ER hormesis [63]. UPR response is essential in regulating satellite cell function during skeletal muscle regeneration [64]; remarkably, ER stress-surviving cells differentiate more efficiently into myotubes [65]. On the other hand, chronic ER and UPR response contribute to the pathogenesis of inflammatory myopathies and genetic diseases characterized by progressive muscle degeneration and weakness [61]. Indeed, some ER stress markers, including GRP78, PERK, eIF2a, IRE1, and sXBP1, are upregulated into skeletal muscle from dystrophic mice [45]. In addition, elevated ER stress is exacerbated during aging, due to the progressive reduction of the expression of ER chaperones in different tissues, including the skeletal muscle [66]. Accordingly, chemical chaperone therapy has been tested in dystrophin-deficient mdx mice in order to reduce the effects of chronic ER stress [46]. We determined that PDI expression is increased in the tibialis anterior muscle of mdx mice, compared to wild-type control (Fig. 1), possibly acting to alleviate ER stress and restore ER homeostasis. We postulated that elevated ER stress in recipient dystrophin-deficient muscle might impair engraftment of transplanted cells in cell-based therapeutic intervention to promote muscular regeneration. Therefore, raising ER stress resistance in transplanted cells might be instrumental in improving cell engraftment in cell therapy procedures. We established that overexpression of PDI promotes survival of transplanted cells to ER stress they face upon transplantation in dystrophin-deficient muscle, enhancing their regenerative potential.

Critical limb ischemia is characterized by markedly reduced blood flow to the extremities and is the most severe and frequent form of peripheral artery disease. Cell therapy represents a promising therapeutic approach for vascular tissue regeneration for ischemic diseases [67]. However, clinical trials indicate consistently modest long-term improvements due, at least in part, to poor survival of transplanted cells [68, 69]. Oxidative stress and ROS generation are essential elements of ER stress [70], induced by physiological stimuli such as hypoxia, glucose, and amino acid deprivation which are critically involved in the early phases of engraftment upon cell transplant [59]. In addition, ER stress has been linked to angiogenesis impairment [51] and endothelial cell dysfunction [52, 53]. Interestingly, PDI is specifically upregulated in endothelial cells to contribute to their ability to tolerate hypoxic stress [54]. Moreover, we have previously determined that PDI protects the heart against ischemic damage [30]. In addition, upregulation of PDI in response to brain ischemia preserves hippocampal cells from apoptosis [71]. Additionally, the use of chemical chaperones mimicking the function of molecular chaperones [72] alleviates ischemia/reperfusion injury [73].

Some cell types, like bone marrow-derived mesenchymal stromal cells, are prone to senescence rather than apoptosis after extensive stress [74], while in others, such as in endothelial cells, ER stress preferentially contributes to apoptosis but not to senescence [75]. PDI expression is decreased in senescent dermal fibroblasts [76] and fetal lung fibroblasts [77], and is lower in stress-induced premature senescent fibroblasts compared to replicative senescent fibroblasts [78]. Conversely, PDI expression is increased in senescent umbilical vein endothelial cells [47, 79, 80]. Moreover, it has been recently described that in endothelial cells PDI has a thiol reductase activity for the dynamin-related protein (Drp1) which regulates mitochondria fission. Therefore, elevated PDI expression should support normal mitochondrial dynamics and endothelial function limiting endothelial cell senescence in the context of pathological conditions such as diabetes mellitus [81].

Collectively, this evidence suggests that PDI plays a protective role in degenerative diseases, in brain ischemia, and in hypoxia, characterized by accumulation of unfolded or misfolded proteins and ER stress. On these bases, we propose that genetic manipulation of transplanted endothelial cells in order to endure ER stress might be instrumental in increasing cell engraftment, promoting the functional recovery by supporting angiogenesis and, consequently, the efficacy of cell therapy for ischemic disease. Here we provide evidence in two relevant models of tissue regeneration, namely muscular degeneration induced by dystrophin deficiency and hindlimb ischemia, that overexpression of PDI in transplanted cells is beneficial for promoting cell survival counteracting ER stress, consequently maximizing the therapeutic benefit of muscular and vascular tissue cell therapy.

Conclusions

Increasing transplanted cell survival by ex vivo PDI gene transfer may be a novel approach to circumvent the poor persistence after implantation, maximizing the therapeutic benefit of cell therapy for muscular and vascular tissue regeneration.

Notes

Abbreviations

BLI: 

Bioluminescent imaging

CD31: 

Cluster of differentiation 31

DMD: 

Duchenne muscular dystrophy

ER: 

Endoplasmic reticulum

GFP: 

Green fluorescent protein

PDI: 

Protein disulfide isomerase

ROS: 

Reactive oxygen species

UPR: 

Unfolded protein response

Declarations

Acknowledgments

The authors thank Stefania Straino and Annalisa Antonini, Vascular Pathology Laboratory, Istituto Dermopatico dell’Immacolata, Rome, Italy, for valuable assistance and Dr Angelo Trivisonno, Department of Surgical Science University “La Sapienza”, Rome, Italy, for providing lipoaspirate samples.

Funding

The study has been funded by a grant awarded by Ministero della Salute-Ricerca Finalizzata (RF-2011-02347907) (to GT). Partial support by Istituto Regina Elena Cinque per Mille (IRE 5 × 1000 2014) (to GT) is also acknowledged. The funding sources had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Availability of data and materials

All data and materials are available from the corresponding author upon request.

Authors’ contributions

SB, GDR, AG, and GT undertook experiments and analyzed the data. GDR and GT wrote the manuscript and conceptualized, designed, and supervised the study. SB, GDR, AG, MC, and GT discussed the results, commented on the draft, and approved the final manuscript.

Ethics approval

The use of human tissues for this research was in compliance with the Helsinki Declaration and approved by the ethics committee of (University “La Sapienza” protocol identification n° 1794/15, 13/02/2015). Animal procedures and maintenance were performed according to the Guidelines of the National Institutes of Health (Art. 31 D.lgs 26/2014, 4 March 2014).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing of interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Research, Advanced Diagnostic and Technological Innovation, IRCCS Regina Elena National Cancer Institute, via E. Chianesi 53, 00144 Rome, Italy
(2)
Vascular Pathology, IRCCS Istituto Dermopatico dell’Immacolata, via dei Monti di Creta 104, 00167 Rome, Italy
(3)
Present address: Department of Systems Medicine, Synaptic Immunopathology Laboratory, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy

References

  1. Shefer G, Van de Mark DP, Richardson JB, Yablonka-Reuveni Z. Satellite-cell pool size does matter: defining the myogenic potency of aging skeletal muscle. Dev Biol. 2006;294(1):50–66.View ArticleGoogle Scholar
  2. Heslop L, Morgan JE, Partridge TA. Evidence for a myogenic stem cell that is exhausted in dystrophic muscle. J Cell Sci. 2000;113(Pt 12):2299–308.PubMedGoogle Scholar
  3. Skuk D, Tremblay JP. Cell therapy in muscular dystrophies: many promises in mice and dogs, few facts in patients. Expert Opin Biol Ther. 2015;15(9):1307–19.View ArticleGoogle Scholar
  4. Loebel C, Burdick JA. Engineering stem and stromal cell therapies for musculoskeletal tissue repair. Cell Stem Cell. 2018;22:325–39.View ArticleGoogle Scholar
  5. de Souza GT, Zanette RS, do Amaral DL, da Guia FC, Maranduba CP, de Souza CM, et al. Satellite cells: regenerative mechanisms and applicability in muscular dystrophy. Stem Cells Int. 2015;2015:487467.View ArticleGoogle Scholar
  6. Chang NC, Chevalier FP, Rudnicki MA. Satellite cells in muscular dystrophy—lost in polarity. Trends Mol Med. 2016;22(6):479–96.View ArticleGoogle Scholar
  7. Blau HM, Webster C, Pavlath GK. Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 1983;80(15):4856–60.View ArticleGoogle Scholar
  8. Decary S, Mouly V, Hamida CB, Sautet A, Barbet JP, Butler-Browne GS. Replicative potential and telomere length in human skeletal muscle: implications for satellite cell-mediated gene therapy. Hum Gene Ther. 1997;8(12):1429–38.View ArticleGoogle Scholar
  9. Gawlik KI. At the crossroads of clinical and preclinical research for muscular dystrophy—are we closer to effective treatment for patients? Int J Mol Sci. 2018;19(5):1490.View ArticleGoogle Scholar
  10. Skuk D, Caron NJ, Goulet M, Roy B, Tremblay JP. Resetting the problem of cell death following muscle-derived cell transplantation: detection, dynamics and mechanisms. J Neuropathol Exp Neurol. 2003;62(9):951–67.View ArticleGoogle Scholar
  11. Bouchentouf M, Benabdallah BF, Bigey P, Yau TM, Scherman D, Tremblay JP. Vascular endothelial growth factor reduced hypoxia-induced death of human myoblasts and improved their engraftment in mouse muscles. Gene Ther. 2008;15(6):404–14.View ArticleGoogle Scholar
  12. Skuk D, Tremblay JP. Cell therapy in myology: dynamics of muscle precursor cell death after intramuscular administration in non-human primates. Mol Ther Methods Clin Dev. 2017;5:232–40.View ArticleGoogle Scholar
  13. Collins CA, Olsen I, Zammit PS, Heslop L, Petrie A, Partridge TA, et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell. 2005;122(2):289–301.View ArticleGoogle Scholar
  14. Montarras D, Morgan J, Collins C, Relaix F, Zaffran S, Cumano A, et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science. 2005;309(5743):2064–7.View ArticleGoogle Scholar
  15. Muir LA, Murry CE, Chamberlain JS. Prosurvival factors improve functional engraftment of myogenically converted dermal cells into dystrophic skeletal muscle. Stem Cells Dev. 2016;25:1559–69.View ArticleGoogle Scholar
  16. Terrill JR, Radley-Crabb HG, Iwasaki T, Lemckert FA, Arthur PG, Grounds MD. Oxidative stress and pathology in muscular dystrophies: focus on protein thiol oxidation and dysferlinopathies. FEBS J. 2013;280(17):4149–64.View ArticleGoogle Scholar
  17. Allen DG, Whitehead NP, Froehner SC. Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol Rev. 2016;96(1):253–305.View ArticleGoogle Scholar
  18. Partridge TA. The mdx mouse model as a surrogate for Duchenne muscular dystrophy. FEBS J. 2013;280(17):4177–86.View ArticleGoogle Scholar
  19. Dumont NA, Wang YX, von Maltzahn J, Pasut A, Bentzinger CF, Brun CE, et al. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat Med. 2015;21(12):1455–63.View ArticleGoogle Scholar
  20. Marshall JL, Holmberg J, Chou E, Ocampo AC, Oh J, Lee J, et al. Sarcospan-dependent Akt activation is required for utrophin expression and muscle regeneration. J Cell Biol. 2012;197(7):1009–27.View ArticleGoogle Scholar
  21. Deldicque L, Hespel P, Francaux M. Endoplasmic reticulum stress in skeletal muscle: origin and metabolic consequences. Exerc Sport Sci Rev. 2012;40(1):43–9.View ArticleGoogle Scholar
  22. Zeeshan HM, Lee GH, Kim HR, Chae HJ. Endoplasmic reticulum stress and associated ROS. Int J Mol Sci. 2016;17(3):327.View ArticleGoogle Scholar
  23. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2008;7(12):1013–30.View ArticleGoogle Scholar
  24. Liu L, Rando TA. Manifestations and mechanisms of stem cell aging. J Cell Biol. 2011;193(2):257–66.View ArticleGoogle Scholar
  25. Okumura M, Kadokura H, Inaba K. Structures and functions of protein disulfide isomerase family members involved in proteostasis in the endoplasmic reticulum. Free Radic Biol Med. 2015;83:314–22.View ArticleGoogle Scholar
  26. Wang L, Wang X, Wang CC. Protein disulfide-isomerase, a folding catalyst and a redox-regulated chaperone. Free Radic Biol Med. 2015;83:305–13.View ArticleGoogle Scholar
  27. Ellgaard L, Ruddock LW. The human protein disulphide isomerase family: substrate interactions and functional properties. EMBO Rep. 2005;6(1):28–32.View ArticleGoogle Scholar
  28. Turano C, Coppari S, Altieri F, Ferraro A. Proteins of the PDI family: unpredicted non-ER locations and functions. J Cell Physiol. 2002;193(2):154–63.View ArticleGoogle Scholar
  29. Perri ER, Thomas CJ, Parakh S, Spencer DM, Atkin JD. The unfolded protein response and the role of protein disulfide isomerase in neurodegeneration. Front Cell Dev Biol. 2016;3:80.View ArticleGoogle Scholar
  30. Severino A, Campioni M, Straino S, Salloum F, Schmidt N, Herbrand U, et al. Identification of protein disulfide isomerase as a cardiomyocyte survival factor in isichemic cardiomyopathy. J Am Coll Cardiol. 2007;50(11):1029–37.View ArticleGoogle Scholar
  31. Carlisle C, Prill K, Pilgrim D. Chaperones and the proteasome system: regulating the construction and demolition of striated muscle. Int J Mol Sci. 2017;19(1):32.View ArticleGoogle Scholar
  32. Gentile A, Toietta G, Pazzano V, Tsiopoulos V, Giglio A, Crea F, et al. Human epicardium-derived cells fuse with high efficiency with skeletal myotubes and differentiate toward the skeletal muscle phenotype: a comparison study with stromal and endothelial cells. Mol Biol Cell. 2011;22(5):581–92.View ArticleGoogle Scholar
  33. Zaccagnini G, Martelli F, Fasanaro P, Magenta A, Gaetano C, Di Carlo A, et al. p66ShcA modulates tissue response to hindlimb ischemia. Circulation. 2004;109(23):2917–23.View ArticleGoogle Scholar
  34. Trivisonno A, Di Rocco G, Cannistra C, Finocchi V, Farr S, Monti M, et al. Harvest of superficial layers of fat with a microcannula and isolation of adipose tissue-derived stromal and vascular cells. Aesthet Surg J. 2014;34(4):601–13.View ArticleGoogle Scholar
  35. Oslowski CM, Urano F. Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol. 2011;490:71–92.View ArticleGoogle Scholar
  36. Natsume Y, Ito S, Satsu H, Shimizu M. Protective effect of quercetin on ER stress caused by calcium dynamics dysregulation in intestinal epithelial cells. Toxicology. 2009;258(2–3):164–75.View ArticleGoogle Scholar
  37. Di Rocco G, Gentile A, Antonini A, Truffa S, Piaggio G, Capogrossi M, et al. Analysis of biodistribution and engraftment into the liver of genetically modified mesenchymal stromal cells derived from adipose tissue. Cell Transplant. 2012;21(9):1997–2008.View ArticleGoogle Scholar
  38. Baldari S, Di Rocco G, Trivisonno A, Samengo D, Pani G, Toietta G. Promotion of survival and engraftment of transplanted adipose tissue-derived stromal and vascular cells by overexpression of manganese superoxide dismutase. Int J Mol Sci. 2016;17(7):1082.View ArticleGoogle Scholar
  39. Di Rocco G, Iachininoto MG, Tritarelli A, Straino S, Zacheo A, Germani A, et al. Myogenic potential of adipose-tissue-derived cells. J Cell Sci. 2006;119(Pt 14):2945–52.View ArticleGoogle Scholar
  40. MacLennan PA, Edwards RH. Protein turnover is elevated in muscle of mdx mice in vivo. Biochem J. 1990;268(3):795–7.View ArticleGoogle Scholar
  41. Rybakova IN, Patel JR, Davies KE, Yurchenco PD, Ervasti JM. Utrophin binds laterally along actin filaments and can couple costameric actin with sarcolemma when overexpressed in dystrophin-deficient muscle. Mol Biol Cell. 2002;13(5):1512–21.View ArticleGoogle Scholar
  42. Hanft LM, Rybakova IN, Patel JR, Rafael-Fortney JA, Ervasti JM. Cytoplasmic gamma-actin contributes to a compensatory remodeling response in dystrophin-deficient muscle. Proc Natl Acad Sci U S A. 2006;103(14):5385–90.View ArticleGoogle Scholar
  43. Hodges BL, Hayashi YK, Nonaka I, Wang W, Arahata K, Kaufman SJ. Altered expression of the alpha7beta1 integrin in human and murine muscular dystrophies. J Cell Sci. 1997;110(Pt 22):2873–81.PubMedGoogle Scholar
  44. Rahkila P, Väänänen K, Saraste J, Metsikkö K. Endoplasmic reticulum to Golgi trafficking in multinucleated skeletal muscle fibers. Exp Cell Res. 1997;234(2):452–64.View ArticleGoogle Scholar
  45. Hulmi JJ, Hentilä J, DeRuisseau KC, Oliveira BM, Papaioannou KG, Autio R, et al. Effects of muscular dystrophy, exercise and blocking activin receptor IIB ligands on the unfolded protein response and oxidative stress. Free Radic Biol Med. 2016;99:308–22.View ArticleGoogle Scholar
  46. Roche J, Mueller A. Chemical chaperone therapy reduces myofiber damage in dystrophin-null mdx mice. FASEB J. 2015;29(Suppl 1):10392.Google Scholar
  47. Pluquet O, Pourtier A, Abbadie C. The unfolded protein response and cellular senescence. A review in the theme: cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. Am J Physiol Cell Physiol. 2015;308(6):C415–25.View ArticleGoogle Scholar
  48. Noren Hooten N, Evans MK. Techniques to induce and quantify cellular senescence. J Vis Exp. 2017;123:e55533. https://doi.org/10.3791/55533.
  49. Chondrogianni N, Gonos ES. Proteasome inhibition induces a senescence-like phenotype in primary human fibroblasts cultures. Biogerontology. 2004;5(1):55–61.View ArticleGoogle Scholar
  50. Iida KI, Miyaishi O, Iwata Y, Kozaki KI, Matsuyama M, Saga S. Distinct distribution of protein disulfide isomerase family proteins in rat tissues. J Histochem Cytochem. 1996;44(7):751–9.View ArticleGoogle Scholar
  51. Binet F, Sapieha P. ER Stress and Angiogenesis. Cell Metab. 2015;22(4):560–75.View ArticleGoogle Scholar
  52. Battson ML, Lee DM, Gentile CL. Endoplasmic reticulum stress and the development of endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2017;312(3):H355–67.View ArticleGoogle Scholar
  53. Cimellaro A, Perticone M, Fiorentino TV, Sciacqua A, Hribal ML. Role of endoplasmic reticulum stress in endothelial dysfunction. Nutr Metab Cardiovasc Dis. 2016;26(10):863–71.View ArticleGoogle Scholar
  54. Graven KK, Molvar C, Roncarati JS, Klahn BD, Lowrey S, Farber HW. Identification of protein disulfide isomerase as an endothelial hypoxic stress protein. Am J Physiol Lung Cell Mol Physiol. 2002;282(5):L996–1003.View ArticleGoogle Scholar
  55. Niiyama H, Huang NF, Rollins MD, Cooke JP. Murine model of hindlimb ischemia. J Vis Exp. 2009;23:1035.Google Scholar
  56. Trivisonno A, Abecassis M, Monti M, Toietta G, Bachir A. Adipose tissue: from energy reservoir to a source of cells for epithelial tissue engineering. In: Shiffman MA, Di Giuseppe A, Bassetto F, editors. Stem cells in aesthetic procedures. Berlin: Springer; 2014. p. 303–26. https://doi.org/10.1007/978-3-642-45207-9_21.View ArticleGoogle Scholar
  57. Moon MH, Kim SY, Kim YJ, Kim SJ, Lee JB, Bae YC, et al. Human adipose tissue-derived mesenchymal stem cells improve postnatal neovascularization in a mouse model of hindlimb ischemia. Cell Physiol Biochem. 2006;17(5–6):279–90.View ArticleGoogle Scholar
  58. Cossu G, Birchall M, Brown T, De Coppi P, Culme-Seymour E, Gibbon S, et al. Lancet commission: stem cells and regenerative medicine. Lancet. 2018;391:883–910.View ArticleGoogle Scholar
  59. Baldari S, Di Rocco G, Piccoli M, Pozzobon M, Muraca M, Toietta G. Challenges and strategies for improving the regenerative effects of mesenchymal stromal cell-based therapies. Int J Mol Sci. 2017;18(10):2087.View ArticleGoogle Scholar
  60. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest. 2005;115(10):2656–64.View ArticleGoogle Scholar
  61. Bohnert KR, McMillan JD, Kumar A. Emerging roles of ER stress and unfolded protein response pathways in skeletal muscle health and disease. J Cell Physiol. 2018;233(1):67–78.View ArticleGoogle Scholar
  62. Afroze D, Kumar A. ER stress in skeletal muscle remodeling and myopathies. FEBS J. 2017. https://doi.org/10.1111/febs.14358.
  63. Mollereau B, Manié S, Napoletano F. Getting the better of ER stress. J Cell Commun Signal. 2014;8(4):311–21.View ArticleGoogle Scholar
  64. Xiong G, Hindi SM, Mann AK, Gallot YS, Bohnert KR, Cavener DR, et al. The PERK arm of the unfolded protein response regulates satellite cell-mediated skeletal muscle regeneration. elife. 2017;6:22871.View ArticleGoogle Scholar
  65. Nakanishi K, Dohmae N, Morishima N. Endoplasmic reticulum stress increases myofiber formation in vitro. FASEB J. 2007;21(11):2994–3003.View ArticleGoogle Scholar
  66. Salminen A, Kaarniranta K. ER stress and hormetic regulation of the aging process. Ageing Res Rev. 2010;9(3):211–7.View ArticleGoogle Scholar
  67. Samura M, Hosoyama T, Takeuchi Y, Ueno K, Morikage N, Hamano K. Therapeutic strategies for cell-based neovascularization in critical limb ischemia. J Transl Med. 2017;15(1):49.View ArticleGoogle Scholar
  68. Qadura M, Terenzi DC, Verma S, Al-Omran M, Hess DA. Concise review: cell therapy for critical limb ischemia: an integrated review of preclinical and clinical studies. Stem Cells. 2018;36:161–71.View ArticleGoogle Scholar
  69. Rigato M, Monami M, Fadini GP. Autologous cell therapy for peripheral arterial disease: systematic review and meta-analysis of randomized, nonrandomized, and noncontrolled studies. Circ Res. 2017;120(8):1326–40.View ArticleGoogle Scholar
  70. Bhandary B, Marahatta A, Kim HR, Chae HJ. An involvement of oxidative stress in endoplasmic reticulum stress and its associated diseases. Int J Mol Sci. 2012;14(1):434–56.View ArticleGoogle Scholar
  71. Tanaka S, Uehara T, Nomura Y. Up-regulation of protein-disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death. J Biol Chem. 2000;275(14):10388–93.View ArticleGoogle Scholar
  72. Kraskiewicz H, FitzGerald U. InterfERing with endoplasmic reticulum stress. Trends Pharmacol Sci. 2012;33(2):53–63.View ArticleGoogle Scholar
  73. Jian L, Lu Y, Lu S, Lu C. Chemical chaperone 4-phenylbutyric acid reduces cardiac ischemia/reperfusion injury by alleviating endoplasmic reticulum stress and oxidative stress. Med Sci Monit. 2016;22:5218–27.View ArticleGoogle Scholar
  74. Alessio N, Del Gaudio S, Capasso S, Di Bernardo G, Cappabianca S, Cipollaro M, et al. Low dose radiation induced senescence of human mesenchymal stromal cells and impaired the autophagy process. Oncotarget. 2015;6(10):8155–66.View ArticleGoogle Scholar
  75. Panganiban RA, Mungunsukh O, Day RM. X-irradiation induces ER stress, apoptosis, and senescence in pulmonary artery endothelial cells. Int J Radiat Biol. 2013;89(8):656–67.View ArticleGoogle Scholar
  76. Boraldi F, Annovi G, Tiozzo R, Sommer P, Quaglino D. Comparison of ex vivo and in vitro human fibroblast ageing models. Mech Ageing Dev. 2010;131(10):625–35.View ArticleGoogle Scholar
  77. Matos L, Gouveia AM, Almeida H. ER stress response in human cellular models of senescence. J Gerontol A Biol Sci Med Sci. 2015;70(8):924–35.View ArticleGoogle Scholar
  78. Aan GJ, Hairi HA, Makpol S, Rahman MA, Karsani SA. Differences in protein changes between stress-induced premature senescence and replicative senescence states. Electrophoresis. 2013;34(15):2209–17.View ArticleGoogle Scholar
  79. Klooster R, Eman MR, le Duc Q, Verheesen P, Verrips CT, Roovers RC, et al. Selection and characterization of KDEL-specific VHH antibody fragments and their application in the study of ER resident protein expression. J Immunol Methods. 2009;342(1–2):1–12.View ArticleGoogle Scholar
  80. Eman MR, Regan-Klapisz E, Pinkse MW, Koop IM, Haverkamp J, Heck AJ, et al. Protein expression dynamics during replicative senescence of endothelial cells studied by 2-D difference in-gel electrophoresis. Electrophoresis. 2006;27(8):1669–82.View ArticleGoogle Scholar
  81. Kim YM, Youn SW, Sudhahar V, Das A, Chandhri R, Cuervo Grajal H, et al. Redox regulation of mitochondrial fission protein Drp1 by protein disulfide isomerase limits endothelial senescence. Cell Rep. 2018;23(12):3565–78.View ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement